New Patent Issued for Orthopedic Stem Cell Procedures

The U.S. Patent Office has issued a patent to Regenexx Corporation which teaches new compositions and methods of promoting the implantation and engraftment of stem cells.

The foundation for this new patent is the fact that tissue repair in vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking.

Regenexx’s new patent teaches compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may well be demonstrating in vitro abilities to expand autologous tissue repair cells.

This patent compliments Regenexx’s same-day cell procedure which has been used to treat joint injuries, spine pain ad degenerative conditions such as osteoarthritis.

Company CEO Christopher Centeno, M.D. said: “Consider this a patent on the use of a ’till the soil’ injection before you plant the seeds (stem cells).” According to a company statement, the patent is key to protecting Regenexx intellectual property as it relates to the company’s proprietary same-day stem cell procedure for orthopedic conditions.

According to the company, Regenexx has published approximately 33% of the world’s peer-reviewed research on the use of stem cells for treating orthopedic conditions.